Who makes TRX518 with pembrolizumab?

TRX518 with pembrolizumab is developed by Leap Therapeutics, Inc..

What development phase is TRX518 with pembrolizumab in?

TRX518 with pembrolizumab is in Phase 1.

Last reviewed 2026-04-19 · How we verify

TRX518 with pembrolizumab

Leap Therapeutics, Inc. · Phase 1 active Small molecule

At a glance

Generic name	TRX518 with pembrolizumab
Sponsor	Leap Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Phase 1 Open-label Study of TRX518 Monotherapy and TRX518 in Combination With Gemcitabine, Pembrolizumab, or Nivolumab (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

TRX518 with pembrolizumab CI brief — competitive landscape report
TRX518 with pembrolizumab updates RSS · CI watch RSS
Leap Therapeutics, Inc. portfolio CI